Inhibrx Biosciences Inc.
INBXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JMP Securities | maintain | Market Perform | Aug 22, 2025 |
| JMP Securities | maintain | Market Perform | May 15, 2025 |
| Citizens Capital Markets | maintain | Market Perform | Mar 18, 2025 |
| JMP Securities | maintain | Market Perform | Jan 22, 2025 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Jan 23, 2024 |
| JMP Securities | maintain | Market Outperform | Nov 20, 2023 |
| JMP Securities | maintain | Outperform | Aug 23, 2023 |
| JMP Securities | maintain | Market Outperform →Outperform | May 10, 2023 |
| JMP Securities | maintain | Market Outperform | Mar 8, 2023 |
| Credit Suisse | maintain | Outperform | Mar 7, 2023 |
| Credit Suisse | maintain | Outperform | Nov 8, 2022 |
| Evercore ISI Group | maintain | Outperform | Oct 5, 2022 |
| SMBC Nikko | maintain | Outperform | Aug 25, 2022 |
| Credit Suisse | maintain | Outperform | Aug 9, 2022 |
| SMBC Nikko | maintain | Outperform | Mar 16, 2022 |
| JMP Securities | maintain | Market Outperform | Mar 2, 2022 |
| Credit Suisse | maintain | Outperform | Nov 10, 2021 |
| JMP Securities | maintain | Market Outperform | Nov 2, 2021 |
| JMP Securities | maintain | Market Outperform →Outperform | Sep 21, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-2.45| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-2.34 | $-2.28 | — | — |
| May 14, 2026 | $-2.15 | $-2.37 | — | — |
| Mar 19, 2026 | $-2.11 | $-2.08 | — | $1.1M |
| Nov 14, 2025 | $-2.28 | $-2.08 | — | — |
| Aug 13, 2025 | $-1.85 | $-2.92 | $1.3M | — |
| May 14, 2025 | $-2.80 | $-2.55 | — | — |
| Mar 17, 2025 | $-3.09 | $-2.88 | $100.0K | — |
| Nov 14, 2024 | $-2.84 | $-3.06 | — | — |
News
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.47 and traded as low as $86.92. Inhibrx Biosciences shares last traded at $88.61, with a volume of 251,182 shares changing hands. Wall Street Analyst Weigh In
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 2026 European Society for Medical Oncology (ESMO) Congress October 25 th , 2026 – Madrid, Spain Title: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart …
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Volatility and Risk Inhibrx Biosciences has a
Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences NASDAQ: INBX CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval date looming, this concentrated insider buying signals a high-probability…
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) rose 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last traded at $103.2880. Approximately 25,880 shares traded hands during trading, a decline of 92% from the average session volume of 318,085 shares. The
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price was up 3.7% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $101.44 and last traded at $103.2880. 25,880 shares were traded during trading, a decline of 92% from the average session volume of 318,085
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The stock was purchased at an average price of $100.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 434,360 shares
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was purchased at an average cost of $100.00 per share, for a total transaction of $500,000.00. Following the transaction, the director owned 429,360 shares of the company's stock,
The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held before the filing.
Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma was accepted by the FDA, with a PDUFA target action date of April 14, 2027. Company reported positive interim data for ozekibart in 3rd/4th-line CRC and strong phase 2 results for INBRX-106 plus KEYTRUDA in HNSCC.
Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data shared yesterday, with pronounced efficacy in HPV+ patients, but market resp…
Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone Results are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab alone Inhibrx will expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a po…
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.